Zobrazeno 1 - 10
of 73
pro vyhledávání: '"M. A. Slavin"'
Autor:
C. Keighley, S. C-A. Chen, D. Marriott, A. Pope, B. Chapman, K. Kennedy, N. Bak, N. Underwood, H. L. Wilson, K. McDonald, J. Darvall, C. Halliday, S. Kidd, Q. Nguyen, K. Hajkowicz, T. C. Sorrell, S. Van Hal, M. A. Slavin
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Candidaemia is associated with high mortality. Variables associated with mortality have been published previously, but not developed into a risk predictive model for mortality. We sought to describe the current epidemiology of can
Externí odkaz:
https://doaj.org/article/54488753a75042e2830e644221f8d91d
Autor:
A G Stewart, SC-A Chen, K Hamilton, T Harris-Brown, T M Korman, M Figtree, L J Worth, J Kok, D Van der Poorten, K Byth, M A Slavin, D L Paterson
Publikováno v:
Open Forum Infectious Diseases.
Background Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality in both healthcare and community settings. Burden and characteristics of disease are not well defined in Australia. We aimed to define the pred
Autor:
M. S. Markin, M. E. Slavin
Publikováno v:
Soil Mechanics and Foundation Engineering. 55:40-42
We consider the possibility of evaluation of the strength characteristics of rocks in the zones of crushing and elevated jointing. We analyze the relationship between the density and the coefficient of water absorption of a representative sample of d
Autor:
O C, Smibert, M A, Slavin, B, Teh, A G, Heriot, J, Penno, H, Ismail, K A, Thursky, L J, Worth
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 28(6)
CRS-HIPEC is associated with improved cancer survival but an increased risk of infection.Consecutive patients undergoing CRS-HIPEC between January 2016 and May 2018 were retrospectively reviewed. Malignancy type, comorbidities, perioperative risk fac
Autor:
E A Ohrtman, L C Simko, E Dore, M D Slavin, C Saret, F Amaya, J Lomelin-Gascon, P Ni, G D Shapiro, A Acton, M Marino, L E Kazis, J C Schneider, C M Ryan
Publikováno v:
Journal of Burn Care & Research. 39:S105-S106
Autor:
M. A. Slavin
Publikováno v:
Internal Medicine Journal. 38:457-467
Autor:
C C, Chang, M, Ananda-Rajah, A, Belcastro, B, McMullan, A, Reid, K, Dempsey, E, Athan, A C, Cheng, M A, Slavin
Publikováno v:
Internal medicine journal. 44(12b)
Healthcare-associated fungal outbreaks impose a substantial economic burden on the health system and typically result in high patient morbidity and mortality, particularly in the immunocompromised host. As the population at risk of invasive fungal in
Autor:
M A, Slavin, K A, Thursky, L J, Worth, C C, Chang, C O, Morrissey, C C, Blyth, S C, Chen, J, Szer
Publikováno v:
Internal medicine journal. 44(12b)
This article introduces the second revision of the Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting. The current update occurs within the context of a growing population at risk of i
Publikováno v:
Internal medicine journal. 44(12b)
Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Crypto
Autor:
S, Fleming, C K, Yannakou, G M, Haeusler, J, Clark, A, Grigg, C H, Heath, A, Bajel, S J, van Hal, S C, Chen, S T, Milliken, C O, Morrissey, C S, Tam, J, Szer, R, Weinkove, M A, Slavin
Publikováno v:
Internal medicine journal. 44(12b)
There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well-tolerat